Mestag Therapeutics Secures Funding for Cancer Research
Mestag Therapeutics, an innovative biotechnology company based in Cambridge, MA, is making impressive strides in the ever-evolving field of cancer therapeutics. Recently, the company was awarded a significant grant of £1.5 million from Innovate UK’s Cancer Therapeutics Program. This funding is intended to expedite the development of MST-0300, a promising antibody that aims to revolutionize the way we approach treatment for patients suffering from cancer and various inflammatory diseases. Under the leadership of CEO Susan Hill, Mestag is dedicating its efforts to generating fresh insights into the intricate interactions between fibroblasts and the immune system, paving the way for the creation of groundbreaking treatments.
Mestag's cutting-edge research focuses on establishing a comprehensive understanding of fibroblast-immune interactions, which are crucial in orchestrating immune responses. The company's pipeline is robust and consists of several antibodies designed to refine and direct the immune system based on both established and emerging biological insights. Among the most notable projects is the bispecific antibody MST-0300, which has been developed through new understandings of tertiary lymphoid structures (TLS) found in solid tumors. These structures play a vital role in enhancing patient outcomes, and MST-0300 aims to leverage this understanding for therapeutic benefit. Additionally, the M402 program targets a stromal checkpoint designed to moderate the activation of specific immune cell subsets, particularly in inflammatory diseases, while earlier programs remain in the discovery phase.
Furthermore, Mestag Therapeutics is embarking on collaborative endeavors to expand its research horizons.
The company is partnering with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, to identify novel therapeutic targets that could lead to the development of next-generation therapies. This collaboration not only highlights Mestag's commitment to innovation in cancer treatment but also its strategic approach to harness existing industry relationships to foster new discoveries. With its strong focus on research and development and a promising pipeline of therapies, Mestag Therapeutics is poised to make a significant impact in the fight against cancer and inflammatory diseases, bringing hope to patients in need.
Click here for a full list of 6,218+ startup investors in the UK